PDCD1 and neoplasm: In vivo studies investigating the treatment with anti-PD-1 or PD-L1 antibodies have reported delayed tumor progression and enhanced viral control accompanied by the reinvigoration of virus-specific T cells in syngeneic murine tumor models and chronic viral infection models, respectively (31, 32).